Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice

Cell Death and Disease

Volumn 4, Issue 7, 2013, Pages

  Kakkola, L ^a   Denisova, O V ^a   Tynell, J ^b   Viiliainen J ^c   Ysenbaert, T ^d   Matos, R C ^a   Nagaraj, A ^a   Ohman T ^c   Kuivanen, S ^e   Paavilainen, H ^f   Feng, L ^g   Yadav, B ^a   Julkunen, I ^b   Vapalahti, O ^e,h   Hukkanen, V ^f   Stenman, J ^g   Aittokallio, T ^a   Verschuren, E W ^a   Ojala, P M ⁱ   Nyman, T ^c   Saelens, X ^e   Dzeyk, K ^j   Kainov, D E ^a   more..

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d GHENT UNIVERSITY   (Belgium)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF TURKU   (Finland)

^g MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ Foundation for the Finnish Cancer Institute   (Finland)

^j EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

more..

Author keywords

Apoptosis; Bcl xL; Cytokines; Infection; Innate immunity; Virus

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; GEMCITABINE; NAVITOCLAX; OBATOCLAX; PATTERN RECOGNITION RECEPTOR; PROTEIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN UACA; TW 37; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SURVIVAL RATE; VIRAL CLEARANCE; VIRUS INFECTION;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; INFLUENZA A VIRUS; MACROPHAGES; MICE; NEOPLASMS; ORTHOMYXOVIRIDAE INFECTIONS; SULFONAMIDES;

EID: 84881053188     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.267     Document Type: Article

References (38)

1. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
2. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121: 2285-2288.
3. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer cell 2013; 23: 139-141.
4. Cullen SP, Martin SJ. Caspase activation pathways: some recent progress. Cell Death Differ 2009; 16: 935-938.
5. Mutlu A, Gyulkhandanyan AV, Freedman J, Leytin V. Activation of caspases-9,-3 and-8 in human platelets triggered by BH3-only mimetic ABT-737 and calcium ionophore A23187: caspase-8 is activated via bypass of the death receptors. Br J Haematol 2012; 159: 565-571.
6. Xiao F, Gao W, Wang X, Chen T. Amplification activation loop between caspase-8 and-9 dominates artemisinin-induced apoptosis of ASTC-a-1 cells. Apoptosis 2012; 17: 600-611.
7. Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 2011; 1813: 558-563.
8. Geng X, Huang C, Qin Y, McCombs JE, Yuan Q, Harry BL et al. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proc Natil Acad Sci US A 2012; 109: 18471-18476.
9. Kraemer BF, Campbell RA, Schwertz H, Franks ZG, Vieira de Abreu A, Grundler K et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood 2012; 120: 5014-5020.
10. Ghigna MR, Reineke T, Rince P, Schuffler P, El Mchichi B, Fabre M et al. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders. Pathobiology 2013; 80: 53-59.
11. Park J, Kang W, Ryu SW, Kim WI, Chang DY, Lee DH et al. Hepatitis C virus infection enhances TNFalpha-induced cell death via suppression of NF-kappaB. Hepatology 2012; 56: 831-840.
12. Busca A, Saxena M, Kumar A. Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis. J Biol Chem 2012; 287: 15118-15133.
13. Pearce AF, Lyles DS. Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL. J Virol 2009; 83: 9102-9112.
14. Tan YX, Tan TH, Lee MJ, Tham PY, Gunalan V, Druce J et al. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. J Virol 2007; 81: 6346-6355.
15. Cheng EH, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA 1997; 94: 690-694.
16. Nencioni L, De Chiara G, Sgarbanti R, Amatore D, Aquilano K, Marcocci ME et al. Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. Journal Biol Chem 2009; 284: 16004-16015.
17. Kepp O, Senovilla L, Galluzzi L, Panaretakis T, Tesniere A, Schlemmer F et al. Viral subversion of immunogenic cell death. Cell Cycle 2009; 8: 860-869.
18. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012; 30: 3127-3135.
19. Herold S, Ludwig S, Pleschka S, Wolff T. Apoptosis signaling in influenza virus propagation, innate host defense, and lung injury. J Leukocyte Biol 2012; 92: 75-82.
20. Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J et al. Obatoclax, saliphenylhalamide and gemcitabine inhibit influenza A virus infection. J Biol Chem 2012; 287: 35324-35332.
21. Muller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, Kainov DE. Emerging cellular targets for influenza antiviral agents. Trends Pharmacol Sci 2012; 33: 89-99.
22. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
23. Follis AV, Chipuk JE, Fisher JC, Yun MK, Grace CR, Nourse A et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat Chem Biol 2013; 9: 163-168.
24. Renault TT, Chipuk JE. Getting away with murder: how does the BCL-2 family of proteins kill with immunity? Ann N Y Acad Sci 2013; 1285: 59-79.
25. Xing Z, Harper R, Anunciacion J, Yang Z, Gao W, Qu B et al. Host immune and apoptotic responses to avian influenza virus H9N2 in human tracheobronchial epithelial cells. Am J Respir Cell Mole Biol 2011; 44: 24-33.
26. Muller KH, Kainov DE, El Bakkouri K, Saelens X, De Brabander JK, Kittel C et al. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. Br J Pharmacol 2011; 164: 344-357.
27. Wies E, Wang MK, Maharaj NP, Chen K, Zhou S, Finberg RW et al. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity 2013; 38: 437-449.
28. Pothlichet J, Meunier I, Davis BK, Ting JP, Skamene E, von Messling V et al. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathogens 2013; 9: e1003256.
29. Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M et al. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 2007; 178: 3368-3372.
30. Lebreton S, Jaunbergs J, Roth MG, Ferguson DA, De Brabander JK. Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide. Bioorg Med Chem Lett 2008; 18: 5879-5883.
31. Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J Biol Chem 2012; 287: 35324-35332.
32. Myoung J, Ganem D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods 2011; 174: 12-21.
33. Myoung J, Ganem D. Infection of lymphoblastoid cell lines by Kaposi's sarcoma-associated herpesvirus: critical role of cell-associated virus. J Virol 2011; 85: 9767-9777.
34. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011; 186: 1022-1031.
35. Lundin M, Lundin J, Helin H, Isola J. A digital atlas of breast histopathology: an application of web based virtual microscopy. J Clin Pathol 2004; 57: 1288-1291.
36. Feng L, Lintula S, Ho TH, Anastasina M, Paju A, Haglund C et al. Technique for strandspecific gene-expression analysis and monitoring of primer-independent cDNA synthesis in reverse transcription. BioTechniques 2012; 52: 263-270.
37. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012; 481: 511-515.
38. Ohman T, Lietzen N, Valimaki E, Melchjorsen J, Matikainen S, Nyman TA. Cytosolic RNA recognition pathway activates 14-3-3 protein mediated signaling and caspase-dependent disruption of cytokeratin network in human keratinocytes. J Proteome Res 2010; 9: 1549-1564.